BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12168842)

  • 1. Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma.
    Koka V; Potti A; Koch M; Fraiman G; Mehdi S; Levitt R
    Anticancer Res; 2002; 22(3):1593-7. PubMed ID: 12168842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
    Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
    Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
    Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R
    Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification and overexpression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1).
    Hermanová M; Lukás Z; Nenutil R; Brázdil J; Kroupová I; Kren L; Pazourková M; Růzicka M; Díte P
    Neoplasma; 2004; 51(2):77-83. PubMed ID: 15190415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of HER2/neu status in Qatari women with breast carcinoma.
    Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
    Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma.
    Slomovitz BM; Broaddus RR; Burke TW; Sneige N; Soliman PT; Wu W; Sun CC; Munsell MF; Gershenson DM; Lu KH
    J Clin Oncol; 2004 Aug; 22(15):3126-32. PubMed ID: 15284264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
    Peredo R; Sastre G; Serrano J; Hunter Mellado R
    Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger.
    Maru D; Middleton LP; Wang S; Valero V; Sahin A
    Cancer; 2005 Mar; 103(5):900-5. PubMed ID: 15643600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-family gene amplification and expression in resected pancreatic cancer.
    te Velde EA; Franke AC; van Hillegersberg R; Elshof SM; de Weger RW; Borel Rinkes IH; van Diest PJ
    Eur J Surg Oncol; 2009 Oct; 35(10):1098-104. PubMed ID: 19304440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.
    Jimenez RE; Hussain M; Bianco FJ; Vaishampayan U; Tabazcka P; Sakr WA; Pontes JE; Wood DP; Grignon DJ
    Clin Cancer Res; 2001 Aug; 7(8):2440-7. PubMed ID: 11489824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma.
    Potti A; Ganti AK; Tendulkar K; Chitajallu S; Sholes K; Koch M; Kargas S
    Anticancer Res; 2003; 23(3B):2671-4. PubMed ID: 12894556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
    Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
    Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma.
    Potti A; Ganti AK; Sholes K; Langness E; Koka V; Horvarth L; Koch M
    Clin Cancer Res; 2003 Oct; 9(13):4872-6. PubMed ID: 14581360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
    Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
    Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
    Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
    Potti A; Ganti AK; Foster H; Knox S; Hebert BJ; Tendulkar K; Sholes K; Koch M; Kargas S
    Anticancer Res; 2004; 24(1):333-7. PubMed ID: 15015617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
    Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.